Sugi Predict

Sugi Predict / Compounds / SCHEMBL4487346

SCHEMBL4487346

SCHEMBL4487346

c1csc(CN2CCCC2)n1

nearest known ligand 0.59

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 2/20 0.59
▸ TSHR P16473 6/20 0.57
▸ ALDH1A1 P00352 4/20 0.57
▸ CYP2C9 P11712 3/20 0.57
▸ CYP2D6 P10635 8/20 0.53
▸ MAPK1 P28482 2/20 0.51
▸ CYP3A4 P08684 8/20 0.51
▸ CYP2C19 P33261 5/20 0.51
▸ LTA4H P09960 1/20 0.50
▸ USP2 O75604 2/20 0.49
▸ CYP1A2 P05177 2/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL807362 0.98 ALOX15 (0.58) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL30341042 0.91 ALOX15 (0.55) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL16221501 0.86 ALOX15 (0.51) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL13940681 0.86 ALOX15 (0.51) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL14338850 0.85 ALOX15 (0.56) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL6482630 0.85 ALOX15 (0.56) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL211751 0.83 ALOX15 (0.72) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL4914558 0.83 ALOX15 (0.72) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL952226 0.83 ALOX15 (0.55) ALOX15TSHRALDH1A1CYP2C9CYP2D6
SCHEMBL6218968 0.82 ALOX15 (0.54) ALOX15TSHRALDH1A1CYP2C9CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 — — US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 — — US disclosed
EP-3381918-B1 7-(THIAZOL-5-YL) PYRROLOPYRIMIDINE COMPOUND AS TLR7 AGONIST CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2020-09-16 — — EP disclosed
US-10676478-B2 7-(thiazol-5-yl) pyrrolopyrimidine compound as TLR7 agonist CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-06-09 — — US disclosed
US-10676478-B2 7-(thiazol-5-yl) pyrrolopyrimidine compound as TLR7 agonist CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-06-09 — — US disclosed
CN-108349982-B 7- (thiazol-5-yl) pyrrolopyrimidine compounds as TLR7 agonists 正大天晴药业集团股份有限公司 2020-05-05 — — CN disclosed
US-20180370976-A1 7-(THIAZOL-5-YL) PYRROLOPYRIMIDINE COMPOUND AS TLR7 AGONIST CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2018-12-27 — — US disclosed
EP-3381918-A1 7-(THIAZOL-5-YL) PYRROLOPYRIMIDINE COMPOUND AS TLR7 AGONIST Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2018-10-03 — — EP disclosed
CN-108349982-A 7- (thiazole -5- bases) Pyrrolopyrimidine compounds as TLR7 agonists 正大天晴药业集团股份有限公司 2018-07-31 — — CN disclosed
CN-107567445-A It can be used as 2 phenyl 3H imidazos [4,5 B] pyridine derivates of mammal EGFR-TK ROR1 activities inhibitor 坎塞拉有限公司 2018-01-09 — — CN disclosed
EP-2049542-B1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-09-19 — — EP disclosed
US-7550486-B2 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2009-06-23 — — US disclosed
US-20080132523-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2008-06-05 — — US disclosed
EP-0711290-A1 METHYLGUANIDINE DERIVATIVES, METHODS FOR PREPARING SAME AND COMPOSITIONS CONTAINING SAID DERIVATIVES SANOFI (FR) 1996-05-15 — — EP disclosed
WO-1995004052-A1 METHYLGUANIDINE DERIVATIVES, METHODS FOR PREPARING SAME AND COMPOSITIONS CONTAINING SAID DERIVATIVES SANOFI (FR) 1995-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180370976-A1 7-(THIAZOL-5-YL) PYRROLOPYRIMIDINE COMPOUND AS TLR7 AGONIST TLR7, TLR9, TLR5 ALOX15 3533/4885TSHR 705/4885ALDH1A1 1624/4885
US-10676478-B2 7-(thiazol-5-yl) pyrrolopyrimidine compound as TLR7 agonist TLR7, TLR9, TLR5 ALOX15 3533/4885TSHR 705/4885ALDH1A1 1624/4885
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 ALOX15 3870/4885TSHR 4347/4885ALDH1A1 4471/4885
US-20080132523-A1 N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ACKR3, CCR7, CCR2 ALOX15 886/4885TSHR 1168/4885ALDH1A1 914/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 ALOX15 3870/4885TSHR 4347/4885ALDH1A1 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.